Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.44 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932199 | 0.84 | SLC6A4 (0.57) | EPHX2KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL21680273 | 0.81 | SLC6A3 (0.45) | EPHX2CYP2D6 | |
| SCHEMBL8119487 | 0.81 | EPHX2 (0.57) | EPHX2CYP2D6KMT2ACYP2C8MEN1 | |
| SCHEMBL28077722 | 0.81 | KMT2A (0.43) | EPHX2CYP2D6KMT2ATET3FBXL19 | |
| SCHEMBL10726449 | 0.81 | SLC6A4 (0.48) | EPHX2CYP2D6HSD11B1P2RX7ALDH1A1 | |
| SCHEMBL16565439 | 0.80 | MEN1 (0.51) | EPHX2CYP2D6KMT2AMEN1 | |
| SCHEMBL21078155 | 0.80 | EPHX2 (0.43) | EPHX2CYP2D6HSD11B1P2RX7 | |
| SCHEMBL16565214 | 0.80 | P2RX7 (0.50) | EPHX2CYP2D6KMT2AP2RX7ALDH1A1 | |
| SCHEMBL3929243 | 0.80 | SLC6A4 (0.60) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL16553797 | 0.77 | EPHX2 (0.41) | EPHX2CYP2D6HSD11B1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | EPHX2 3339/4885CYP2D6 806/4885KMT2A 1848/4885 |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | EPHX2 3339/4885CYP2D6 806/4885KMT2A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.